These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 33649098)
1. Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. Scolari F; Delbarba E; Santoro D; Gesualdo L; Pani A; Dallera N; Mani LY; Santostefano M; Feriozzi S; Quaglia M; Boscutti G; Ferrantelli A; Marcantoni C; Passerini P; Magistroni R; Alberici F; Ghiggeri GM; Ponticelli C; Ravani P; J Am Soc Nephrol; 2021 Apr; 32(4):972-982. PubMed ID: 33649098 [TBL] [Abstract][Full Text] [Related]
2. Membranous Nephropathy: It Is Time to Go Back to the Future. Sabiu G; Podestà MA Nephron; 2021; 145(6):721-727. PubMed ID: 34225270 [TBL] [Abstract][Full Text] [Related]
3. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Fernández-Juárez G; Rojas-Rivera J; Logt AV; Justino J; Sevillano A; Caravaca-Fontán F; Ávila A; Rabasco C; Cabello V; Varela A; Díez M; Martín-Reyes G; Diezhandino MG; Quintana LF; Agraz I; Gómez-Martino JR; Cao M; Rodríguez-Moreno A; Rivas B; Galeano C; Bonet J; Romera A; Shabaka A; Plaisier E; Espinosa M; Egido J; Segarra A; Lambeau G; Ronco P; Wetzels J; Praga M; Kidney Int; 2021 Apr; 99(4):986-998. PubMed ID: 33166580 [TBL] [Abstract][Full Text] [Related]
4. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial. Scolari F; Dallera N; Gesualdo L; Santoro D; Pani A; Santostefano M; Feriozzi S; Mani LY; Boscutti G; Messa P; Magistroni R; Quaglia M; Ponticelli C; Ravani P BMJ Open; 2019 Dec; 9(12):e029232. PubMed ID: 31806605 [TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831 [TBL] [Abstract][Full Text] [Related]
6. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series. Cortazar FB; Leaf DE; Owens CT; Laliberte K; Pendergraft WF; Niles JL BMC Nephrol; 2017 Feb; 18(1):44. PubMed ID: 28143416 [TBL] [Abstract][Full Text] [Related]
7. Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis. Bose B; Chung EYM; Hong R; Strippoli GFM; Johnson DW; Yang WL; Badve SV; Palmer SC J Nephrol; 2022 May; 35(4):1159-1170. PubMed ID: 35199314 [TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. von Groote TC; Williams G; Au EH; Chen Y; Mathew AT; Hodson EM; Tunnicliffe DJ Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004293. PubMed ID: 34778952 [TBL] [Abstract][Full Text] [Related]
9. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up. Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365 [TBL] [Abstract][Full Text] [Related]
10. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). Fervenza FC; Canetta PA; Barbour SJ; Lafayette RA; Rovin BH; Aslam N; Hladunewich MA; Irazabal MV; Sethi S; Gipson DS; Reich HN; Brenchley P; Kretzler M; Radhakrishnan J; Hebert LA; Gipson PE; Thomas LF; McCarthy ET; Appel GB; Jefferson JA; Eirin A; Lieske JC; Hogan MC; Greene EL; Dillon JJ; Leung N; Sedor JR; Rizk DV; Blumenthal SS; Lasic LB; Juncos LA; Green DF; Simon J; Sussman AN; Philibert D; Cattran DC; Nephron; 2015; 130(3):159-68. PubMed ID: 26087670 [TBL] [Abstract][Full Text] [Related]
11. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study. Yan P; Fang X; Ke B Int Immunopharmacol; 2024 Mar; 130():111718. PubMed ID: 38377859 [TBL] [Abstract][Full Text] [Related]
12. Primary membranous nephropathy in the Italian region of Emilia Romagna: results of a multicenter study with extended follow-up. Albertazzi V; Fontana F; Giberti S; Aiello V; Battistoni S; Catapano F; Graziani R; Cimino S; Scichilone L; Forcellini S; De Fabritiis M; Sara S; Delsante M; Fiaccadori E; Mosconi G; Storari A; Mandreoli M; Bonucchi D; Buscaroli A; Mancini E; Rigotti A; La Manna G; Gregorini M; Donati G; Cappelli G; Scarpioni R; J Nephrol; 2024 Mar; 37(2):471-482. PubMed ID: 37957455 [TBL] [Abstract][Full Text] [Related]
13. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395 [TBL] [Abstract][Full Text] [Related]
14. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC; N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies. Ou JY; Chen YW; Li TL; Shan HZ; Cui S; Lai JJ; Xiao Y Nephrol Ther; 2022 Apr; 18(2):104-112. PubMed ID: 35074299 [TBL] [Abstract][Full Text] [Related]
16. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. Ponticelli C; Altieri P; Scolari F; Passerini P; Roccatello D; Cesana B; Melis P; Valzorio B; Sasdelli M; Pasquali S; Pozzi C; Piccoli G; Lupo A; Segagni S; Antonucci F; Dugo M; Minari M; Scalia A; Pedrini L; Pisano G; Grassi C; Farina M; Bellazzi R J Am Soc Nephrol; 1998 Mar; 9(3):444-50. PubMed ID: 9513907 [TBL] [Abstract][Full Text] [Related]
17. Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy. Rojas-Rivera J; Fervenza FC; Ortiz A Drugs; 2022 Feb; 82(2):109-132. PubMed ID: 34932208 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis. Lu W; Gong S; Li J; Luo H; Wang Y Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997 [TBL] [Abstract][Full Text] [Related]
20. Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population. Anjum N; Nabi Z; Alam MA J Ayub Med Coll Abbottabad; 2019; 31(2):265-268. PubMed ID: 31094128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]